Doravirine vs Etravirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Doravirine · Pifeltro

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT02275780 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)

Result source: NCT02403674

Etravirine · Intelence

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00254046 · Phase 3 · completed

Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.

Reported efficacy

Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)

Result source: NCT00254046

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDoravirineEtravirine
HIV-1 RNA below 50 copies/mL (week 48)83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
56% vs 39%a+17 vs placebowk 24NCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778—Not posted · NCT00255099
CD4 count, change (week 48)224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
—Not posted · NCT00255099

HIV-1 RNA below 50 copies/mL (week 48)

Doravirine
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
Etravirine
56% vs 39%a+17 vs placebowk 24NCT00254046

HIV-1 RNA 50 copies/mL or more (week 48)

Doravirine
0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778
Etravirine
—Not posted · NCT00255099

CD4 count, change (week 48)

Doravirine
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
Etravirine
—Not posted · NCT00255099
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Doravirine: 7 of 7 rows · Etravirine: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDoravirine
Rows use multiple source trials
Etravirine
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
42.5 cells/uL @ 96wka,b,c
NCT03332095 · Phase 1/2 · combination
224 cells/uL @ 96wk400 mg once dailya,b,c
NCT00959894 · Phase 2 · registry result, not featured evidence
2 other source trials
18.5 cells/uL @ 96wk
NCT00128830 · Phase 2 · registry result, not featured evidence
120 cells/uL @ 96wk
NCT00128830 · Phase 2 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.1 log @ 48wka,b,c
NCT03332095 · Phase 1/2 · combination
-1.53 log @ 48wka,b,c
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
97.6% (n=42) @ 48wka,b
NCT03332095 · Phase 1/2 · combination
45.5% (n=22) @ 48wk400/100 mgd,a,b
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
50% (n=22) @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
24.2%100 mge
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
19.6%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
10%Cohort 1: DOR
NCT03332095 · Phase 1/2
2.2%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
20.4%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
8.2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
0%
NCT04689737 · Phase 4 · registry result, not featured evidence
30.4%DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
80.2%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
17%Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
42.9%DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
33.3%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
43.6%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
28.6%
NCT04900974 · Phase 1 · registry result, not featured evidence
0%
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
n/a: no completion milestonef
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
20.3%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
36%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
40%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
24.8%
NCT00665847 · Phase 2 · registry result, not featured evidence
20.3%
NCT00903682 · Phase 2 · registry result, not featured evidence
34.1%
NCT00128830 · Phase 2 · registry result, not featured evidence
5%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
1.6%100 mge
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
3%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
—Cohort 1: DOR
NCT03332095 · Phase 1/2
—Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
—200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
6.7%f
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
3.8%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
4%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
8%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
7.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
7.6%
NCT00903682 · Phase 2 · registry result, not featured evidence
4.7%
NCT00128830 · Phase 2 · registry result, not featured evidence
—Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
—
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Serious AEs
11.7%100 mge
NCT02275780 · Phase 3 · combination
show 44 more results
6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
6%DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
4.5%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
5.2%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
6.3%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
8.2%DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
—MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
0%Cohort 1: DOR
NCT03332095 · Phase 1/2
4.4%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
10.6%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
25%
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
4.3%DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
6.2%DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.6%DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.5%DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
6.4%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
5.3%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.1%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
0%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.7%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.8%Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
4%Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
3.7%Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
2.7%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
10.2%100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
7.3%200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
2.3%50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
10%25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
0%
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
10%f
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
15.2%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
8%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
16%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
5%
NCT00665847 · Phase 2 · registry result, not featured evidence
13.9%
NCT00903682 · Phase 2 · registry result, not featured evidence
21.8%
NCT00128830 · Phase 2 · registry result, not featured evidence
25%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
50%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
0%200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
20%
NCT01427504 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
100 mge
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · combination
show 33 more results
nasopharyngitis 13.7%
upper respiratory tract infection 7.2%
headache 6.2%
NCT02403674 · Phase 3 · HIV · phase 3
headache 15.9%
diarrhoea 13.7%
nasopharyngitis 13.7%
NCT02403674 · Phase 3 · HIV · phase 3
nasopharyngitis 9.7%
upper respiratory tract infection 7.1%
diarrhoea 6.3%
NCT02403674 · Phase 3 · HIV · phase 3
dizziness 38.2%
diarrhoea 15.9%
headache 15.4%
NCT02403674 · Phase 3 · HIV · phase 3
aspartate aminotransferase increased 22.2%
blood alkaline phosphatase increased 11.1%
blood glucose increased 11.1%
NCT03332095 · Phase 1/2
glomerular filtration rate decreased 55.6%
alanine aminotransferase increased 46.7%
blood creatinine increased 46.7%
NCT03332095 · Phase 1/2 · combination
100 mg
creatinine renal clearance decreased 10.6%
low density lipoprotein increased 6.4%
abdominal pain upper 2.1%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
100 mg
creatinine renal clearance decreased 8.2%
aspartate aminotransferase increased 4.1%
alanine aminotransferase increased 2%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
vomiting 25%
headache 12.5%
NCT04689737 · Phase 4 · registry result, not featured evidence
headache 8.1%
covid-19 5.9%
arthralgia 5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 13.1%
lymphocyte count decreased 10.5%
cd4 lymphocytes decreased 9.2%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 32.3%
cd4 lymphocytes decreased 23.7%
covid-19 12.4%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 15.9%
cd4 lymphocytes decreased 11.4%
covid-19 1.5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 2.6%
nasopharyngitis 2%
diarrhoea 1%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
100 mg/0.75 mg
covid-19 14.1%
headache 10.4%
lymphocyte count decreased 9.1%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 24.1%
cd4 lymphocytes decreased 10.5%
covid-19 7.5%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 17.1%
cd4 lymphocytes decreased 8.2%
upper respiratory tract infection 2.7%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 14.3%
accidental overdose 0%
arthralgia 0%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
upper respiratory tract infection 6.3%
insomnia 1.8%
headache 0.9%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
headache 10.7%
accidental overdose 7.1%
covid-19 5.4%
NCT04223778 · Phase 3 · registry result, not featured evidence
lymphocyte count decreased 20.2%
cd4 lymphocytes decreased 14%
covid-19 13%
NCT04223778 · Phase 3 · registry result, not featured evidence
covid-19 17.5%
lymphocyte count decreased 13.5%
cd4 lymphocytes decreased 12%
NCT04223778 · Phase 3 · registry result, not featured evidence
blood creatine phosphokinase increased 28.6% (placebo 14.3%)
diarrhoea 28.6% (placebo 14.3%)
anaemia 14.3% (placebo 0%)
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
dizziness 33.3%
dyspepsia 33.3%
headache 33.3%
NCT04295772 · Phase 2 · registry result, not featured evidence
covid-19 100%
adjustment disorder 0%
back pain 0%
NCT04295772 · Phase 2 · registry result, not featured evidence
oropharyngeal pain 10.8%
cough 8.1%
nasal congestion 8.1%
NCT04295772 · Phase 2 · registry result, not featured evidence
cough 28.6%
oropharyngeal pain 21.4%
rhinorrhoea 21.4%
NCT04295772 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 17.6%
diarrhea 14.8%
dizziness 14.8%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 29.3%
nausea 22%
headache 17.1%
NCT01632345 · Phase 2 · registry result, not featured evidence
50 mg
abnormal dreams 20.9%
nausea 16.3%
headache 14%
NCT01632345 · Phase 2 · registry result, not featured evidence
25 mg
diarrhea 25%
fatigue 17.5%
influenza 15%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 33.3%)
abdominal pain 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
25 mg
alanine aminotransferase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 0%)
decreased appetite 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
f
cough 2.8%
upper respiratory tract infection 2.8%
pregnancy 2.2%
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
400 mg once daily
elevated level of transaminase 11.4%
hyperbilirubinemia 7.6%
hyperlipidemia 7.6%
NCT00959894 · Phase 2 · registry result, not featured evidence
400/100 mg
cough 16%
headache 12%
influenza 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
300/100 mg
cough 20%
nausea 16%
blood bilirubin increased 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 26.7%
diarrhoea 15.8%
cough 12.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
nasopharyngitis 21.5%
headache 16.5%
diarrhoea 10.1%
NCT00903682 · Phase 2 · registry result, not featured evidence
diarrhoea 17.5%
upper respiratory tract infection 17.1%
sinusitis 11.4%
NCT00128830 · Phase 2 · registry result, not featured evidence
blood bicarbonate decreased 90%
blood sodium decreased 70%
nasal congestion 70%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
cough 100%
nasal congestion 100%
rhinorrhoea 100%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
200 mg + 200 mg
headache 18.8%
toothache 12.5%
diarrhoea 6.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
200 mg + 600/100 mg + 200 mg
rash maculo-papular 20%
scleral hyperaemia 20%
headache 13.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
headache 14.3%
constipation 10.7%
diarrhea 7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
breast tenderness 66.7%
diarrhea 11.1%
headache 11.1%
NCT01625169 · Phase na · registry result, not featured evidence · combination
altered taste 64%
headache 16%
rash 16%
NCT01427504 · Phase na · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 1/2 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for 24 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Doravirine

CD4+ 192.7 vs 185.6 Daurunavir + Ritonavir cells/uL @ 48wk100 mg
absolute change · cells/uL
NCT02275780 · Phase 3 · combination
show 14 more results
224.1 vs 206.7 Daurunavir + Ritonavir cells/uL @ 96wk100 mg
NCT02275780 · Phase 3 · combination
133.6 vs 121.1 Efavirenz cells/uL @ 24wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
152.3 vs 146 Efavirenz cells/uL @ 24wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
191.9 vs 194.5 Efavirenz cells/uL @ 48wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
259.2 vs 263.6 Efavirenz cells/uL @ 96wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
140.7 vs 121.1 Efavirenz cells/uL @ 24wk200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
182.4 vs 233.5 BIC/FTC/TAF cells/uL @ 48wk100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
217.05 vs 319.92 BIC/FTC/TAF cells/uL @ 96wk100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
239.6 vs 350.9 BIC/FTC/TAF cells/uL @ 144wk100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
112.9 vs 121.1 Efavirenz cells/uL @ 24wk50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
154.1 vs 121.1 Efavirenz cells/uL @ 24wk25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
-19.66 vs 40.51 BIC/FTC/TAF cells/uL @ 48wk
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
5.36 vs 62.67 BIC/FTC/TAF cells/uL @ 96wk
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0.48 vs 66.25 BIC/FTC/TAF cells/uL @ 144wk
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Non-HDL-C Change mg/dL -5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HDL-C Change mg/dL 3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Total Cholesterol Change mg/dL -1.37 mg/dL @ 48wk100 mg
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02275780 · Phase 3 · combination
Triglyceride Change mg/dL -3.14 vs 21.97 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HIV-1 RNA Less Than 40 Copies 83.3% (n=383) vs 79.1% (n=383) Daurunavir + Ritonavir @ 48wk100 mg
responder rate · % of participants
NCT02275780 · Phase 3 · combination
show 3 more results
72% (n=379) vs 64.4% (n=376) Daurunavir + Ritonavir @ 96wk100 mg
NCT02275780 · Phase 3 · combination
83.8% (n=364) vs 79.7% (n=364) ATRIPLA @ 48wk
NCT02403674 · Phase 3 · HIV · phase 3
76.1% (n=364) vs 72.8% (n=364) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
CD4+ 198.4% (n=344) vs 188.4% (n=329) ATRIPLA @ 48wk
absolute change · percentage points
NCT02403674 · Phase 3 · HIV · phase 3
show 3 more results
237.7% (n=337) vs 223% (n=311) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
-0.7% (n=313) vs 8.7% (n=311) Baseline Antiretroviral Therapy (ART) @ 48wk
NCT04223778 · Phase 3 · registry result, not featured evidence
5.29% (n=289) vs 0.16% (n=285) Baseline Antiretroviral Therapy (ART) @ 96wk
NCT04223778 · Phase 3 · registry result, not featured evidence
LDL-C -1.58% (n=330) vs 8.74% (n=305) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Non-HDL-C -3.83% (n=333) vs 13.26% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Total Cholesterol -1.97% (n=333) vs 21.77% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Triglycerides -12.4% (n=333) vs 22.01% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3

+ 39 further endpoints in the CSV export.

Etravirine

HIV-1 RNA Less Than 50 Copies 0.87% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.77% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.71% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 0.89% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.82% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.77% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
CD4 46 count @ 4wk400/100 mg
absolute change · count
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
72 count @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
83 count @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
132 count @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
55 count @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
31 count @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
54 count @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
105 count @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Virological Response 50 Copies Snapshot 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA -1.8 copies/mL @ 4wk400/100 mg
absolute change · copies/mL
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
-2 copies/mL @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.9 copies/mL @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.7 copies/mL @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Time to Viral Suppression 2.5 months400/100 mg
time to event · months
No placebo or comparator arm
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 76 days as posted
show 1 more result
2.33 months*300/100 mg
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 71 days as posted
Time to Virologic Failure NA months400/100 mg
time to event · months
No placebo or comparator arm
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
10.45 months*300/100 mg
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 318 days as posted
Virologic 52.5% (n=101) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies Per 75.9% (n=79) vs 74.4% (n=78) Efavirenz @ 48wk
event count · % of participants
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 60 Number of participants as posted
show 1 more result
81% (n=79) vs 79.5% (n=78) Efavirenz @ 48wk*
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 64 Number of participants as posted
CD4 69.96 vs 72.45 Efavirenz count @ 2wk
absolute change · count
NCT00903682 · Phase 2 · registry result, not featured evidence
show 5 more results
128.14 vs 121.62 Efavirenz count @ 6wk
NCT00903682 · Phase 2 · registry result, not featured evidence
143.24 vs 151.46 Efavirenz count @ 12wk
NCT00903682 · Phase 2 · registry result, not featured evidence
182.01 vs 174.08 Efavirenz count @ 24wk
NCT00903682 · Phase 2 · registry result, not featured evidence
213.45 vs 180.18 Efavirenz count @ 36wk
NCT00903682 · Phase 2 · registry result, not featured evidence
205.11 vs 221.39 Efavirenz count @ 48wk
NCT00903682 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 58% (n=181) @ 96wk
responder rate · % of participants
No placebo or comparator arm
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 105 Participants as posted
show 1 more result
70.4% (n=98) @ 192wk*
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 69 Participants as posted
HIV-1 RNA Less Than 400 Copies 68.5% (n=181) @ 96wk
responder rate · % of participants
No placebo or comparator arm
Viral load less than 400 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 124 Participants as posted

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Etravirine's landscape